• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA to post inspection information online

FDA to post inspection information online

June 2, 2011
CenterWatch Staff

The FDA will publish more details about inspections and court actions on its web site as part of a drive toward transparency, according to a report on InPharm.

A web portal and database has been sent up to make the FDA enforcement and compliance-related activities “more accessible, downloadable, and searchable online," said the agency.

The move stems from the FDA Transparency Initiative, set up in 2009, and comes shortly after President Obama's direction to federal enforcement agencies to improve public access to information about their activities, made earlier this year.

The FDA said it will provide more information about company practices that may jeopardize public health and help consumers make decisions about products based on recall and enforcement activities.

Shining a light on inspection results will also help "to create a greater incentive to bring practices into compliance with the law," it added.

The database includes the name and address of inspected facilities, the dates of inspection, the type of FDA-regulated products involved and the outcome of the inspection, as well as summaries of the most common observations noted.

For example, in 2010 the three most common issues noted in inspections of drug facilities were the lack of clear, written quality control procedures, failure to follow standard operating procedures (SOPs) and failure to investigate batch failures.

By the end of the year, the FDA will also begin to disclose additional information about 'Untitled Letters,' which are an initial correspondence with a company citing violations that do not meet the threshold of regulatory significance for a full-blown warning letter.

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing